Instil Bio, Inc. reported second quarter 2026 financial results on August 13, 2026. The company held $69.9 million in cash and marketable securities as of June 30, 2026, sufficient to fund operations beyond 2027. For the six months ended June 30, 2026, Instil reported a net loss of $8.5 million ($1.25 per share), compared to a net loss of $49.6 million ($7.55 per share) in the prior year period. Research and development expenses decreased significantly to $0.9 million from $12.1 million, while general and administrative expenses fell to $10.5 million from $15.3 million. The company is evaluating potential acquisitions and in-licensing opportunities for novel therapeutic candidates. Instil Bio operates in the biotechnology industry, focusing on identifying and advancing innovative therapeutics.